clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2024-102-1-57-61clinmed-735Research ArticleВ ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУGUIDELINES FOR PRACTITIONERSПобочные эффекты ингибиторов протонного насоса: насколько они реальны в клинической практике?Side effects of proton pump inhibitors: how real are they in clinical practice?https://orcid.org/0000-0002-1395-9566ШептулинА. А.SheptulinA. A.

Шептулин Аркадий Александрович — д-р мед. наук, профессор, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского

Москва

Arkadiy A. Sheptulin — Doctor of Medical Sciences, Professor, Professor of the Department of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology of the Institute of Clinical Medicine named after N.V. Sklifosovsky

Moscow

arkalshep@gmail.comКириловскийА. А.KirilovskyA. A.

Кириловский Алексей Александрович — врач-терапевт

Москва

Aleksey A. Kirilovsky — physician 

Moscow

КириловскаяК. С.KirilovskayaK. S.

Кириловская Ксения Сергеевна — клинический ординатор кафедры общей врачебной практики Института клинической медицины им. Н.В. Склифосовского

Москва

Ksenia S. Kirilovskaya — clinical resident of the Department of General Medical Practice of the Institute of Clinical Medicine named after. N.V. Sklifosovsky

Moscow

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia (Sechenov University)Russian FederationАО «Семейный доктор»РоссияFamily DoctorRussian Federation20241504202410215761Copyright © Шептулин А.А., Кириловский А.А., Кириловская К.С., 20242024Шептулин А.А., Кириловский А.А., Кириловская К.С.Sheptulin A.A., Kirilovsky A.A., Kirilovskaya K.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/735

В представленной статье обсуждается риск возникновения побочных эффектов при применении ингибиторов протонного насоса (ИПН): инфекционных осложнений (синдром избыточного бактериального роста в тонкой кишке, Clostridiumdiffi  cile-ассоциированная болезнь, спонтанный бактериальный перитонит, внебольничная пневмония), рак желудка, инфаркт миокарда, гипомагниемия, дефицит железа и витамина В12, поражение почек, переломы костей, деменция, болезнь Альцгеймера. Анализ литературы свидетельствует о слабой причинной связи возникновения данных заболеваний с приемом ИПН. Тем не менее необходимо стремиться к назначению данных препаратов в минимальной эффективной дозе и возможно более короткое время.

The presented article discusses the risk of side eff ects when using proton pump inhibitors (PPI): infectious complications (small intestinal bacterial overgrowth, Clostridium difficile-associated disease, community-acquired pneumonia, spontaneous bacterial peritonitis), stomach cancer, myocardial infarction, hypomagnesemia, iron and vitamin B12 deficiency, kidney damage, bone fractures, dementia, Alzheimer’s disease. An analysis of the literature indicates a weak causal relationship between the occurrence of these diseases and the use of PPI. Nevertheless, it is necessary to strive for the appointment of these drugs in the minimum effective dose and for as short a time as possible.

ингибиторы протонного насосапобочные эффектыбезопасность примененияproton pump inhibitorsside effectssafety of applicationReferencesTurner J.P., Thompson W., Reeve E., Bell J.S. Deprescribing proton pump inhibitors. Aust. J. Gen. Pract. 2022;51(11):845–848. DOI: 10.31128/AJGP-07-22-649Turner J.P., Thompson W., Reeve E., Bell J.S. Deprescribing proton pump inhibitors. Aust. J. Gen. Pract. 2022;51(11):845–848. DOI: 10.31128/AJGP-07-22-649Strand D.S., Kim D., Peura D.F. 25 years of proton pump inhibitors: A comprehensive review. Gut Liver. 2017;11(1):27–37. DOI: 10.5009/gnl15Strand D.S., Kim D., Peura D.F. 25 years of proton pump inhibitors: A comprehensive review. Gut Liver. 2017;11(1):27–37. DOI: 10.5009/gnl15Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J. Gastroenterol. 2015;21(22):6817–6819. DOI: 10.3748/wjg.v21.i22.6817Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J. Gastroenterol. 2015;21(22):6817–6819. DOI: 10.3748/wjg.v21.i22.6817Kiecka A., Szczanik M. Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics. Pharmacol. Rep. 2023 ;75(4):791–804. DOI: 10.1007/s43440-023-00489-xKiecka A., Szczanik M. Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics. Pharmacol. Rep. 2023 ;75(4):791–804. DOI: 10.1007/s43440-023-00489-xMcDonald E.G., Milligan J., Frenette C., Lee T.C. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern. Med. 2015;175(5):784–791. DOI: 10.1001/jamainternmed.2015.4McDonald E.G., Milligan J., Frenette C., Lee T.C. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern. Med. 2015;175(5):784–791. DOI: 10.1001/jamainternmed.2015.4Kwok C.S., Arthur A.S., Anibueze C.I., Sungh S., Cavalkazzi R., Loke Y.K. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am. J. Gastroenterol. 2012;107(7):1011–1019. DOI: 10.1038/ajg.2012.108Kwok C.S., Arthur A.S., Anibueze C.I., Sungh S., Cavalkazzi R., Loke Y.K. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am. J. Gastroenterol. 2012;107(7):1011–1019. DOI: 10.1038/ajg.2012.108Tawam D., Baladi M., Jungsuwadee P., Earl G., Han J. The рositive association between proton pump inhibitors and Clostridium difficile infection. Innov. Pharm. 2021;12(1):10.24926/iip.v12i1.3439. DOI: 10.24926/iip.v12i1.3439Tawam D., Baladi M., Jungsuwadee P., Earl G., Han J. The рositive association between proton pump inhibitors and Clostridium difficile infection. Innov. Pharm. 2021;12(1):10.24926/iip.v12i1.3439. DOI: 10.24926/iip.v12i1.3439Haastrup P.F., Thompson W., Sondergaard J., Jarbol D.E. Side effects of long-term proton pump inhibitor use: A review. Basic Clin. Pharmacol. Toxicol. 2018;123(2):114–121. DOI: 10.1111/bcpt.13023Haastrup P.F., Thompson W., Sondergaard J., Jarbol D.E. Side effects of long-term proton pump inhibitor use: A review. Basic Clin. Pharmacol. Toxicol. 2018;123(2):114–121. DOI: 10.1111/bcpt.13023Fatima K., Almas T., Lakhani S. Jahangir A., Ahmed A. Siddiqui A. et al. The use of proton pump inhibitors and COVID-19: A systematic review and meta-analysis. Trop. Med. Infect Dis. 2022;7(3):37. DOI: 10.3390/tropicalmed7030037Fatima K., Almas T., Lakhani S. Jahangir A., Ahmed A. Siddiqui A. et al. The use of proton pump inhibitors and COVID-19: A systematic review and meta-analysis. Trop. Med. Infect Dis. 2022;7(3):37. DOI: 10.3390/tropicalmed7030037Lundell L., Vieth M., Gibson F., Nagy P., Kahrilas P.J. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Alliment. Pharmacol. Ther. 2015;42(6):649–663. DOI: 10.1111/apt.13324Lundell L., Vieth M., Gibson F., Nagy P., Kahrilas P.J. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Alliment. Pharmacol. Ther. 2015;42(6):649–663. DOI: 10.1111/apt.13324Ahn J.S., Eom C.-S., Jeon C.S., Park S.M. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J. Gastroenterol. 2013;19(16):2560–2568. DOI: 10.3748/wjg.v19.i16.2560Ahn J.S., Eom C.-S., Jeon C.S., Park S.M. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J. Gastroenterol. 2013;19(16):2560–2568. DOI: 10.3748/wjg.v19.i16.2560Guo H., Zhang R., Zhang P. Chen Z., Hua Y., Huang X., Li X. Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis. Front. Pharmacol. 2023;14:1129948. DOI: 10.3389/fphar.2023.1129948Guo H., Zhang R., Zhang P. Chen Z., Hua Y., Huang X., Li X. Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis. Front. Pharmacol. 2023;14:1129948. DOI: 10.3389/fphar.2023.1129948Gao H., Li L., Geng K., Teng C., Chen Y., Chu F., Zhao Y. Use of proton pump inhibitors for the risk of gastric cancer. Medicine (Baltimore). 2022;101(49):e32228. DOI: 10.1097/MD.0000000000032228Gao H., Li L., Geng K., Teng C., Chen Y., Chu F., Zhao Y. Use of proton pump inhibitors for the risk of gastric cancer. Medicine (Baltimore). 2022;101(49):e32228. DOI: 10.1097/MD.0000000000032228Brusselaers N., Wahlin K., Engstrand L., Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739. DOI: 10.1136/bmjopen-2017-017739Brusselaers N., Wahlin K., Engstrand L., Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739. DOI: 10.1136/bmjopen-2017-017739Crafa P., Franceschi M., Rodrigues-Castro K.I., Franzoni L., Russo M., Brandimarte G. et al. PPIs and gastric cancer: any causal relationship? Biomed. 2023;94(3):e2023096. DOI: 10.23750/abm.v94i3.14105Crafa P., Franceschi M., Rodrigues-Castro K.I., Franzoni L., Russo M., Brandimarte G. et al. PPIs and gastric cancer: any causal relationship? Biomed. 2023;94(3):e2023096. DOI: 10.23750/abm.v94i3.14105Shih C.-J., Chen Y.-T., Ou S.-Y., Li S,-Y., Chen T.-J., Wang S.-J. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int. J. Cardiol. 2014;177(1):292–297. DOI: 10.1016/j.ijcard.2014.09.036Shih C.-J., Chen Y.-T., Ou S.-Y., Li S,-Y., Chen T.-J., Wang S.-J. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int. J. Cardiol. 2014;177(1):292–297. DOI: 10.1016/j.ijcard.2014.09.036Ariel H., Cooke J.P. Cardiovascular risk of proton pump inhibitors. Methodist Debakey Cardiovasc. J. 2019;15(3):214–219. DOI: 10.14797/mdcj-15-3-21418Ariel H., Cooke J.P. Cardiovascular risk of proton pump inhibitors. Methodist Debakey Cardiovasc. J. 2019;15(3):214–219. DOI: 10.14797/mdcj-15-3-21418Lee D., Kim J.S., Kim B.J., Shin S.Y., Kim D.B., Ahn H.S. Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention. Medicine (Baltimore). 2021;100(52):e27411. DOI: 10.1097/MD.0000000000027411Lee D., Kim J.S., Kim B.J., Shin S.Y., Kim D.B., Ahn H.S. Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention. Medicine (Baltimore). 2021;100(52):e27411. DOI: 10.1097/MD.0000000000027411Han Y.-Y., Li Z.-X., Duan R. Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis. Rev. Cardiovasc. Med. 2021;22(1):167–174. DOI: 10.31083/j.rcm.2021.01.296Han Y.-Y., Li Z.-X., Duan R. Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis. Rev. Cardiovasc. Med. 2021;22(1):167–174. DOI: 10.31083/j.rcm.2021.01.296Shi D., Zhou Z., Dai Y., Pan X., Cao Q. Proton pump inhibitor therapy and hepatic encephalopathy risk in cirrhotic patients: A systematic review with meta-analysis. Clin. Drug Investig. 2019;39(9):847–856. DOI:10.1007/s40261-019-00810-8Shi D., Zhou Z., Dai Y., Pan X., Cao Q. Proton pump inhibitor therapy and hepatic encephalopathy risk in cirrhotic patients: A systematic review with meta-analysis. Clin. Drug Investig. 2019;39(9):847–856. DOI:10.1007/s40261-019-00810-8Kuan Y.-C., Huang K.-W., Lin C.-L., Luo J.-C., Kao C.-H. Short-term proton pump inhibitor use and hepatic encephalopathy risk in patients with decompensated cirrhosis. J. Clin. Med. 2019;8(8):1108. DOI: 10.3390/jcm8081108Kuan Y.-C., Huang K.-W., Lin C.-L., Luo J.-C., Kao C.-H. Short-term proton pump inhibitor use and hepatic encephalopathy risk in patients with decompensated cirrhosis. J. Clin. Med. 2019;8(8):1108. DOI: 10.3390/jcm8081108Nochaiwong S., Ruengorn C., Awiphan R., Koyratkoson K., Chasai C., Noppakun K. et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol. Dial. Transplant. 2018;33(2):331–342. DOI: 10.1093/ndt/gfw470Nochaiwong S., Ruengorn C., Awiphan R., Koyratkoson K., Chasai C., Noppakun K. et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol. Dial. Transplant. 2018;33(2):331–342. DOI: 10.1093/ndt/gfw470Hart E., Dunn T.E., Feuerstein S., Jacobs D.M. Proton pump inhibitors and risk of acute and chronic kidney disease: A retrospective cohort study. Pharmacotherapy. 2019;39(4):443–453. DOI: 10.1002/phar.2235Hart E., Dunn T.E., Feuerstein S., Jacobs D.M. Proton pump inhibitors and risk of acute and chronic kidney disease: A retrospective cohort study. Pharmacotherapy. 2019;39(4):443–453. DOI: 10.1002/phar.2235Morschel C.F., Mafra D., Carraro Eduardo J.C. The relationship between proton pump inhibitors and renal disease. J. Bras. Nefrol. 2018;40(3):301–306. DOI: 10.1590/2175-8239-jbn-2018-0021Morschel C.F., Mafra D., Carraro Eduardo J.C. The relationship between proton pump inhibitors and renal disease. J. Bras. Nefrol. 2018;40(3):301–306. DOI: 10.1590/2175-8239-jbn-2018-0021Schiffl H., Al-Nemnem Е., Lang S.M. Proton-pump inhibitors and chronic kidney disease: Hidden consequences of an inappropriate drug use? Saudi J. Kidney Dis. Transpl. 2020;31(2):312–319. DOI: 10.4103/1319-2442.284005Schiffl H., Al-Nemnem Е., Lang S.M. Proton-pump inhibitors and chronic kidney disease: Hidden consequences of an inappropriate drug use? Saudi J. Kidney Dis. Transpl. 2020;31(2):312–319. DOI: 10.4103/1319-2442.284005Guedes J.V.M., Aquino J.A., Castro T.L.B., de Morais F.A., Baldoni A.O., Belo V.S., Otoni A. Omeprazole use and risk of chronic kidney disease evolution. PLoS One. 2020;15(3):e0229344 DOI: 10.1371/journal.pone.0229344Guedes J.V.M., Aquino J.A., Castro T.L.B., de Morais F.A., Baldoni A.O., Belo V.S., Otoni A. Omeprazole use and risk of chronic kidney disease evolution. PLoS One. 2020;15(3):e0229344 DOI: 10.1371/journal.pone.0229344Kamal F., Khan M.A., Molnar M.Z., Howden C.W. The association between proton pump inhibitor use with acute kidney injury and chronic kidney disease. J. Clin. Gastroenterol. 2018;52(6):468–476. DOI: 10.1097/MCG.000000000000103528Kamal F., Khan M.A., Molnar M.Z., Howden C.W. The association between proton pump inhibitor use with acute kidney injury and chronic kidney disease. J. Clin. Gastroenterol. 2018;52(6):468–476. DOI: 10.1097/MCG.000000000000103528Cheema E. Investigating the association of proton pump inhibitors with chronic kidney disease and its impact on clinical practice and future research: a review. J. Pharm. Policy Pract. 2019;12:6. DOI: 10.1186/s40545-019-0167-0Cheema E. Investigating the association of proton pump inhibitors with chronic kidney disease and its impact on clinical practice and future research: a review. J. Pharm. Policy Pract. 2019;12:6. DOI: 10.1186/s40545-019-0167-0Gommers L.M.M., Hoenderop J.G., de Baaij J.H.F. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol. (Oxf). 2022;235(4):e13846. DOI: 10.1111/apha.13846Gommers L.M.M., Hoenderop J.G., de Baaij J.H.F. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol. (Oxf). 2022;235(4):e13846. DOI: 10.1111/apha.13846Lam J.R., Schneider J.L., Zhao W., Corley D.A. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B 12 deficiency. JAMA. 2013;310(22):2435–2442. DOI: 10.1001/jama.2013.280490Lam J.R., Schneider J.L., Zhao W., Corley D.A. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B 12 deficiency. JAMA. 2013;310(22):2435–2442. DOI: 10.1001/jama.2013.280490Swarnakari K.M., Bai M., Manoharan M.P., Raja R., Jamil A., Csendes D. et al. The effects of proton pump inhibitors in acid hypersecretion-induced vitamin B 12 defi ciency: A systematic review (2022). Cureus. 2022;14(11):e31672. DOI: 10.7759/cureus.31672Swarnakari K.M., Bai M., Manoharan M.P., Raja R., Jamil A., Csendes D. et al. The effects of proton pump inhibitors in acid hypersecretion-induced vitamin B 12 defi ciency: A systematic review (2022). Cureus. 2022;14(11):e31672. DOI: 10.7759/cureus.31672den Elzen W.P.J., Groeneveld Y., de Ruijter W., Souverijn J.H.M., le Cessie S., Assendelft J., Gussekloo J. Long-term use of proton pump inhibitors and vitamin B 12 status in elderly individuals. Aliment. Pharmacol. Ther. 2008;27(6):491–497. DOI: 10.1111/j.1365-2036.2008.03601.xden Elzen W.P.J., Groeneveld Y., de Ruijter W., Souverijn J.H.M., le Cessie S., Assendelft J., Gussekloo J. Long-term use of proton pump inhibitors and vitamin B 12 status in elderly individuals. Aliment. Pharmacol. Ther. 2008;27(6):491–497. DOI: 10.1111/j.1365-2036.2008.03601.xBrigant S.J., Naciu A.V., Tabacco G., Cesareo R., Napoli N. Trimboli P. et al. Proton pump inhibitors and fractures in adults: A critical appraisal and review of the literature. J. Endocrinol. 2021;2021:8902367. DOI: 10.1155/2021/8902367Brigant S.J., Naciu A.V., Tabacco G., Cesareo R., Napoli N. Trimboli P. et al. Proton pump inhibitors and fractures in adults: A critical appraisal and review of the literature. J. Endocrinol. 2021;2021:8902367. DOI: 10.1155/2021/8902367Li M., Luo Z., Yu S., Tang Z. Proton pump inhibitor use and risk of dementia: Systematic review and meta-analysis. Medicine (Baltimore). 201998(7):e14422. DOI: 10.1097/MD.0000000000014422Li M., Luo Z., Yu S., Tang Z. Proton pump inhibitor use and risk of dementia: Systematic review and meta-analysis. Medicine (Baltimore). 201998(7):e14422. DOI: 10.1097/MD.0000000000014422Vaezy M.F., Yang Y.-X., Howden C.W. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48. DOI: 10.1053/j.gastro.2017.04.047Vaezy M.F., Yang Y.-X., Howden C.W. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48. DOI: 10.1053/j.gastro.2017.04.047

The authors declare that there are no conflicts of interest present.